Early Life and Education
Alexey Repik was born on August 27, 1979, in Moscow, Russia. He graduated from the Higher School of Economics in 2003 with a degree in economics and enterprise management. During his studies, he worked as an economist in a city hospital, which gave him insights into the healthcare sector.
Rise to Success
Repik's career in healthcare began in 1995. He founded R-Pharm in 2001, with an initial investment of $40,000. R-Pharm quickly became a major player in the pharmaceutical market, and Repik expanded the company by establishing branches across Russia. In 2017, Mitsui & Co., Ltd. acquired a 10% share of R-Pharm for $200 million. Repik's company was involved in the production of a vaccine against COVID-19 for AstraZeneca.
Key Business Strategies
A key strategy for R-Pharm was the establishment of high-quality, local drug production in Russia, which helped to reduce the country's reliance on imports. R-Pharm formed strategic partnerships with leading global pharmaceutical companies, including Pfizer, Bayer, and Sanofi. Repik also focused on research and development, particularly in oncology, immunology, and rare diseases, positioning R-Pharm as an innovative company.
Philanthropy
Repik is involved in philanthropy. He is donating for construction of a large shelter for 1,500 dogs per year in Yaroslavl, a city 250 kilometers from Moscow. He also co-founded the fund "Utoli Moya Pechali" with the Russian Orthodox Church, providing assistance to hospitals, orphans, and children from low-income families, as well as people with disabilities.
